RPRXNasdaqPharmaceutical PreparationsUS GAAP · USD

Royalty Pharma plc

Royalty Pharma plc is a U.S.-listed biopharmaceutical royalty company organized through a holding-company structure in England and Wales. It acquires and holds royalty interests and other interests tied to the sales of approved medicines and development-stage therapies, generating returns from the top-line performance of those products across global markets.

Kysy yhtiöstä
Liikevaihto2 378milj. USD
+5,1 %v/v
Liikevoitto (EBIT)1 560milj. USD
+20,7 %v/v
EBIT-marginaali65,6%
+8,5 %-yks.v/v
Nettotulos771milj. USD
−10,2 %v/v
Vapaa kassavirta2 490milj. USD
−10,1 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

05001 0001 5002 0002 500milj. USD2020: 2 122 milj. USD2020: EBIT 1 595 milj. USD20202021: 2 289 milj. USD2021: EBIT 1 431 milj. USD20212022: 2 237 milj. USD2022: EBIT 307 milj. USD20222023: 2 355 milj. USD2023: EBIT 1 492 milj. USD20232024: 2 264 milj. USD2024: EBIT 1 292 milj. USD20242025: 2 378 milj. USD2025: EBIT 1 560 milj. USD20252 3781 560
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Royalty Pharma plc

Liiketoiminta

Osuus liikevaihdosta
Commercial royalty interests70 %

Royalties tied to sales of marketed biopharmaceutical products.

Development-stage royalty interests15 %

Interests linked to product candidates that may generate future royalties.

Synthetic royalties10 %

Royalty-like interests created by biotech companies on existing therapies.

Other biopharmaceutical interests5 %

Additional royalty receivables, intangible interests, and related assets.

Tuotteet

Raportoitu · osuus liikevaihdosta
95,1%FY2025100 %
  • Financial Royalty Assets95,1 %
  • Royalty Income Other4,9 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Royalty Pharma's counterparties are biopharmaceutical innovators rather than end patients: academic institutions, research hospitals, not-for-profits, biotechnology companies, and large pharmaceutical companies that monetize future product sales. It also depends on the marketers and payors of the underlying drugs, since royalty receipts are driven by the commercial success of those therapies.

Biotechnology companies

They sell royalty interests or synthetic royalties to raise non-dilutive capital while retaining operational control of programs.

Large pharmaceutical companies

They market approved therapies that generate royalty payments on commercial sales.

Academic and research institutions

They monetize intellectual property from discoveries and early-stage programs.

Research hospitals and not-for-profits

They license or sell royalty rights tied to therapeutic innovations.

Drug payors and reimbursement systems

They do not buy from the company, but their pricing and reimbursement decisions determine royalty-bearing sales.

Strategia

Royalty Pharma focuses on selectively acquiring royalty streams on important therapies and product candidates, using its scale and specialist underwriting to source transactions. It also emphasizes capital allocation discipline, portfolio diversification across products and stages, and participation in the growing market for synthetic royalties.

Expand the royalty portfolioKeskipitkä aikaväli

A broader portfolio reduces dependence on any single product and increases exposure to multiple therapeutic franchises.

Target high-quality innovationKeskipitkä aikaväli

Royalties on therapies addressing unmet needs are more likely to sustain commercialization and pricing power.

Grow synthetic royalty activityLyhyt aikaväli

Synthetic royalties are an expanding source of deal flow as biotech companies seek non-dilutive capital.

Maintain disciplined capital allocationPitkä aikaväli

Returns depend on buying royalty streams at attractive prices relative to expected future cash flows.

Maantiede

Royalty Pharma is incorporated in England and Wales, but its business is global because the underlying therapies are sold in major pharmaceutical markets worldwide. The company specifically highlights exposure to the U.S., EU, UK, Japan, and China through the pricing and reimbursement systems that affect royalty-generating products.

Riskit

The business depends on the commercial success of third-party biopharmaceutical products, so patent loss, generic or biosimilar competition, pricing pressure, and regulatory exclusivity changes can reduce royalty income. It also faces structural and financial risks from leverage, foreign exchange, interest rates, and the holding-company model, while accounting outcomes depend heavily on estimates of future royalty cash flows.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Sales risk on royalty-bearing products1Patent, exclusivity, and competition risk2Pricing and reimbursement pressure3Interest rate, FX, and leverage risk4Royalty market and acquisition risk5Holding-company and organizational structure risk6
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Sales risk on royalty-bearing productsVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Royalty receipts depend on third-party products remaining commercially successful.

    Kohdistuu: Commercial therapies in the portfolio

  2. Patent, exclusivity, and competition riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Generics, biosimilars, or loss of exclusivity can reduce or eliminate royalty streams.

    Kohdistuu: Products with finite exclusivity periods

  3. Pricing and reimbursement pressureVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Drug pricing scrutiny and payer decisions can limit sales growth and royalty value.

    KohdistuuU.SEUUKJapanChina
  4. Interest rate, FX, and leverage riskVaikutus: KeskitasoTodennäköisyys: Korkea

    Capital deployment and financing costs can affect returns and reported results.

    Kohdistuu: Debt-funded investments and global cash flows

  5. Royalty market and acquisition riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Future returns depend on sourcing attractive royalty assets in a competitive market.

    Kohdistuu: New royalty acquisitions and development-stage deals

  6. Holding-company and organizational structure riskVaikutus: KeskitasoTodennäköisyys: Matala

    Cash generation and obligations flow through subsidiaries and related entities.

    Kohdistuu: Corporate structure and internalization-related arrangements

Kysy Clarifolta: Royalty Pharma plc

Kirjanpito

Harkinnanvaraiset erät
Financial royalty asset valuation

Carrying values and interest income depend on forecasts of future royalty receipts.

Vaikutus: Can materially affect revenue recognition and asset balances

Prospective effective interest method

Interest income is recognized based on updated expected cash flows from royalty assets.

Vaikutus: Affects timing and amount of reported income

Impairment of royalty interests

Weaker product sales or loss of exclusivity can require write-downs.

Vaikutus: Can reduce earnings and asset values

Classification between financial and intangible assets

Different royalty structures are accounted for differently depending on rights acquired.

Vaikutus: Changes presentation, amortization, and measurement

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

XOMA Royalty Corp

Pharmaceutical Preparations

Xenetic Biosciences, Inc.

XBIO · Pharmaceutical Preparations

Provectus Biopharmaceuticals, Inc.

PVCT · Pharmaceutical Preparations

Propanc Biopharma, Inc.

PPCB · Pharmaceutical Preparations

Silence Therapeutics plc

SLNCF · Pharmaceutical Preparations

Xencor Inc

XNCR · Pharmaceutical Preparations

Päivitetty: 24.9.2026

Royalty Pharma plc (RPRX) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo